September 11, 2026

Consolidated Financial Results for the Fiscal Year Ended July 31, 2026 (Under Japanese GAAP)

Company name: Pharma Foods International Co., Ltd.
Listing: Tokyo Stock Exchange
Securities code: 2929
URL: https://www.pharmafoods.co.jp/
Representative: Mujo Kim, President
Inquiries: Kosuke Torio, Executive Managing Director, Business Support & Promotion Department
Telephone: +81-75-394-8600
Scheduled date of annual general meeting of shareholders: October 28, 2026
Scheduled date to commence dividend payments: October 30, 2026
Scheduled date to file annual securities report: October 23, 2026
Preparation of supplementary material on financial results: Yes
Holding of financial results briefing: Yes (for institutional investors and analysts)

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the fiscal year ended July 31, 2026 (from August 1, 2025 to July 31, 2026)

(1) Consolidated operating results

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Fiscal year ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
July 31, 2026	63,223	(3.1)	2,632	11.2	2,440	(4.4)	1,988	439.1
July 31, 2025	65,260	5.0	2,367	(53.7)	2,553	(51.3)	368	(88.5)

Note: Comprehensive income For the fiscal year ended July 31, 2026: ¥2,160 million [-%]
For the fiscal year ended July 31, 2025: ¥(3) million [(100.1)%]

	Basic earnings per share	Diluted earnings per share	Return on equity	Ratio of ordinary profit to total assets	Ratio of operating profit to net sales
Fiscal year ended	Yen	Yen	%	%	%
July 31, 2026	68.61	-	16.1	7.2	4.2
July 31, 2025	12.83	-	3.1	7.4	3.6

Reference: Share of profit (loss) of entities accounted for using equity method
For the fiscal year ended July 31, 2026: ¥(203) million
For the fiscal year ended July 31, 2025: ¥(131) million

(2) Consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio	Net assets per share
As of	Millions of yen	Millions of yen	%	Yen
July 31, 2026	35,115	13,166	37.5	453.35
July 31, 2025	32,649	11,547	35.4	399.95

Reference: Equity
As of July 31, 2026: ¥13,166 million
As of July 31, 2025: ¥11,547 million

(3) Consolidated cash flows

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents at end of period
Fiscal year ended	Millions of yen	Millions of yen	Millions of yen	Millions of yen
July 31, 2026	(1,175)	(4,000)	3,808	7,691
July 31, 2025	(1,092)	(950)	(4,467)	9,057

2. Cash dividends

	Annual dividends per share					Total cash dividends (Total)	Payout ratio (Consolidated)	Ratio of dividends to net assets (Consolidated)
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total			
	Yen	Yen	Yen	Yen	Yen	Millions of yen	%	%
Fiscal year ended July 31, 2025	-	12.50	-	12.50	25.00	724	194.8	6.2
Fiscal year ended July 31, 2026	-	12.50	-	12.50	25.00	726	36.4	5.9
Fiscal year ending July 31, 2027 (Forecast)		12.50		12.50	25.00		33.0	

Note: Revision from the most recently published dividend forecast: None

3. Forecast of consolidated financial results for the fiscal year ending July 31, 2027 (from August 1, 2026 to July 31, 2027)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Fiscal year ending July 31, 2027	64,000	1.2	3,000	14.0	3,400	39.3	2,200	10.7	75.75

From the perspective of promoting constructive dialogue aimed at increasing corporate value over the medium to long term, the Company has set a full-year earnings forecast only.

*** Notes**

(1) Significant changes in the scope of consolidation during the period: None

(2) Changes in accounting policies, changes in accounting estimates, and restatement

(i) Changes in accounting policies due to revisions to accounting standards and other regulations: None

(ii) Changes in accounting policies due to other reasons: None

(iii) Changes in accounting estimates: None

(iv) Restatement: None

(3) Number of issued shares (common shares)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of July 31, 2026	29,079,000 shares
As of July 31, 2025	29,079,000 shares

(ii) Number of treasury shares at the end of the period

As of July 31, 2026	35,623 shares
As of July 31, 2025	206,978 shares

(iii) Average number of shares outstanding during the period

Fiscal year ended July 31, 2026	28,978,455 shares
Fiscal year ended July 31, 2025	28,742,537 shares

[Reference] Overview of non-consolidated financial results

1. Non-consolidated financial results for the fiscal year ended July 31, 2026 (from August 1, 2025 to July 31, 2026)

(1) Non-consolidated operating results

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit	
Fiscal year ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
July 31, 2026	40,867	(3.2)	153	(97.8)	311	(95.7)	(237)	-
July 31, 2025	42,234	3.9	7,004	66.9	7,213	65.6	2,732	(1.1)

	Basic earnings per share	Diluted earnings per share
Fiscal year ended	Yen	Yen
July 31, 2026	(8.20)	-
July 31, 2025	95.07	-

(2) Non-consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio	Net assets per share
As of	Millions of yen	Millions of yen	%	Yen
July 31, 2026	32,540	15,551	47.8	535.45
July 31, 2025	36,316	16,227	44.7	562.05

Reference: Equity
As of July 31, 2026: ¥15,551 million
As of July 31, 2025: ¥16,227 million

* Financial results reports are exempt from audit conducted by certified public accountants or an audit firm.

* Proper use of earnings forecasts, and other special matters

The forward-looking statements, including forecasts of financial results, contained in these materials are based on information available to the Company and on certain assumptions deemed to be reasonable. Actual financial results may differ from the results anticipated in the statements due to various factors. For the assumptions and other matters related to the above forecasts, please refer to "1. Please refer to "Summary of Business Results (4) Future Outlook".

The Company plans to hold a financial results briefing for institutional investors, analysts, and business partners on September 28, 2026. The financial results briefing materials to be distributed at this briefing will be posted on TDnet and the Company's website on the day of the event.

Consolidated balance sheet

(Millions of yen)

	As of July 31, 2025	As of July 31, 2026
Assets		
Current assets		
Cash and deposits	9,157	7,791
Notes and accounts receivable - trade	5,038	3,916
Electronically recorded monetary claims - operating	247	74
Merchandise and finished goods	6,311	7,533
Work in process	675	820
Raw materials and supplies	864	790
Other	1,576	2,102
Allowance for doubtful accounts	(0)	(0)
Total current assets	23,870	23,029
Non-current assets		
Property, plant and equipment		
Buildings and structures, net	2,082	2,068
Machinery, equipment and vehicles, net	708	619
Tools, furniture and fixtures, net	518	441
Land	1,194	1,196
Leased assets, net	27	20
Construction in progress	164	3,671
Total property, plant and equipment	4,696	8,018
Intangible assets		
Goodwill	71	37
Other	49	48
Total intangible assets	120	85
Investments and other assets		
Investment securities	2,450	2,670
Deferred tax assets	515	630
Other	996	681
Total investments and other assets	3,961	3,982
Total non-current assets	8,778	12,085
Total assets	32,649	35,115

(Millions of yen)

	As of July 31, 2025	As of July 31, 2026
Liabilities		
Current liabilities		
Notes and accounts payable - trade	1,923	1,413
Short-term borrowings	11,400	13,400
Current portion of long-term borrowings	560	560
Accounts payable - other	3,520	1,292
Income taxes payable	1,494	418
Provision for bonuses	72	74
Other	1,034	1,107
Total current liabilities	20,005	18,265
Non-current liabilities		
Long-term borrowings	671	3,211
Retirement benefit liability	378	374
Other	45	96
Total non-current liabilities	1,096	3,682
Total liabilities	21,101	21,948
Net assets		
Shareholders' equity		
Share capital	2,043	2,043
Capital surplus	1,814	1,814
Retained earnings	7,691	8,969
Treasury shares	(195)	(26)
Total shareholders' equity	11,353	12,800
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	193	365
Total accumulated other comprehensive income	193	365
Total net assets	11,547	13,166
Total liabilities and net assets	32,649	35,115

Consolidated statement of income

(Millions of yen)

	Fiscal year ended July 31, 2025	Fiscal year ended July 31, 2026
Net sales	65,260	63,223
Cost of sales	12,676	12,530
Gross profit	52,583	50,693
Selling, general and administrative expenses		
Research and development expenses	1,399	1,858
Advertising expenses	36,692	33,917
Commission expenses	4,431	4,896
Amortization of goodwill	53	34
Other	7,638	7,353
Total selling, general and administrative expenses	50,215	48,060
Operating profit	2,367	2,632
Non-operating income		
Interest income	6	18
Dividend income	32	38
Foreign exchange gains	-	1
Subsidy income	250	208
Gain on investments in investment partnerships	1	-
Outsourcing service income	16	6
Compensation income	109	-
Other	54	100
Total non-operating income	472	373
Non-operating expenses		
Interest expenses	91	161
Foreign exchange losses	1	-
Loss on investments in investment partnerships	-	2
Share of loss of entities accounted for using equity method	131	203
Commission expenses	18	155
Other	42	42
Total non-operating expenses	286	565
Ordinary profit	2,553	2,440
Extraordinary income		
Gain on sale of non-current assets	-	4
Total extraordinary income	-	4
Extraordinary losses		
Loss on valuation of investment securities	118	-
Loss on sale of shares of subsidiaries and associates	-	117
Total extraordinary losses	118	117
Profit before income taxes	2,434	2,327
Income taxes - current	2,256	480
Income taxes - deferred	(190)	(141)
Total income taxes	2,066	338
Profit	368	1,988
Profit attributable to owners of parent	368	1,988

Consolidated statement of comprehensive income

(Millions of yen)

	Fiscal year ended July 31, 2025	Fiscal year ended July 31, 2026
Profit	368	1,988
Other comprehensive income		
Valuation difference on available-for-sale securities	(372)	171
Total other comprehensive income	(372)	171
Comprehensive income	(3)	2,160
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	(3)	2,160

Consolidated statement of changes in equity

Fiscal year ended July 31, 2025

(Millions of yen)

	Shareholders' equity					Accumulated other comprehensive income		Total net assets
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity	Valuation difference on available-for-sale securities	Total accumulated other comprehensive income	
Balance at beginning of period	2,043	1,814	8,356	(1,194)	11,019	566	566	11,585
Changes during period								
Dividends of surplus			(784)		(784)			(784)
Profit (loss) attributable to owners of parent			368		368			368
Purchase of treasury shares				(175)	(175)			(175)
Disposal of treasury shares		(249)		1,174	924			924
Transfer from retained earnings to capital surplus		249	(249)		-			-
Net changes in items other than shareholders' equity						(372)	(372)	(372)
Total changes during period	-	-	(665)	999	333	(372)	(372)	(38)
Balance at end of period	2,043	1,814	7,691	(195)	11,353	193	193	11,547

Consolidated statement of changes in equity

Fiscal year ended July 31, 2026

(Millions of yen)

	Shareholders' equity					Accumulated other comprehensive income		Total net assets
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity	Valuation difference on available-for-sale securities	Total accumulated other comprehensive income	
Balance at beginning of period	2,043	1,814	7,691	(195)	11,353	193	193	11,547
Changes during period								
Dividends of surplus			(723)		(723)			(723)
Profit (loss) attributable to owners of parent			1,988		1,988			1,988
Purchase of treasury shares					-			-
Disposal of treasury shares		13		169	183			183
Transfer from retained earnings to capital surplus		(13)	13		-			-
Net changes in items other than shareholders' equity						171	171	171
Total changes during period	-	-	1,278	169	1,447	171	171	1,619
Balance at end of period	2,043	1,814	8,969	(26)	12,800	365	365	13,166

Consolidated statement of cash flows

(Millions of yen)

	Fiscal year ended July 31, 2025	Fiscal year ended July 31, 2026
Cash flows from operating activities		
Profit before income taxes	2,434	2,327
Depreciation	732	702
Amortization of goodwill	53	34
Increase (decrease) in allowance for doubtful accounts	(1)	(0)
Increase (decrease) in retirement benefit liability	(5)	(4)
Increase (decrease) in provision for bonuses	(0)	2
Interest and dividend income	(38)	(56)
Subsidy income	(250)	(208)
Interest expenses	91	161
Compensation income	(109)	-
Loss (gain) on sale of non-current assets	-	(4)
Loss (gain) on investments in investment partnerships	(1)	2
Foreign exchange losses (gains)	(0)	(1)
Share of loss (profit) of entities accounted for using equity method	131	203
Loss on valuation of investment securities	118	-
Loss (gain) on sale of shares of subsidiaries and associates	-	117
Decrease (increase) in trade receivables	(988)	1,294
Decrease (increase) in inventories	(1,133)	(1,293)
Decrease (increase) in consumption taxes refund receivable	(575)	91
Increase (decrease) in trade payables	673	(510)
Increase (decrease) in accounts payable - other	(394)	(2,228)
Increase (decrease) in accrued consumption taxes	187	(105)
Other, net	(70)	672
Subtotal	851	1,195
Interest and dividends received	38	56
Interest paid	(91)	(161)
Subsidies received	246	161
Proceeds from compensation	109	-
Income taxes paid	(2,247)	(2,528)
Income taxes refund	-	100
Net cash provided by (used in) operating activities	(1,092)	(1,175)

(Millions of yen)

	Fiscal year ended July 31, 2025	Fiscal year ended July 31, 2026
Cash flows from investing activities		
Purchase of property, plant and equipment	(891)	(4,014)
Proceeds from sale of property, plant and equipment	-	9
Purchase of intangible assets	(15)	(15)
Purchase of investment securities	(64)	(69)
Proceeds from sale of investment securities	0	-
Proceeds from redemption of investment securities	-	100
Other, net	21	(9)
Net cash provided by (used in) investing activities	(950)	(4,000)
Cash flows from financing activities		
Net increase (decrease) in short-term borrowings	(3,500)	2,000
Proceeds from long-term borrowings	-	3,100
Repayments of long-term borrowings	(760)	(560)
Dividends paid	(784)	(723)
Purchase of treasury shares	(175)	-
Proceeds from disposal of treasury shares	761	-
Other, net	(8)	(7)
Net cash provided by (used in) financing activities	(4,467)	3,808
Effect of exchange rate change on cash and cash equivalents	0	1
Net increase (decrease) in cash and cash equivalents	(6,509)	(1,365)
Cash and cash equivalents at beginning of period	15,566	9,057
Cash and cash equivalents at end of period	9,057	7,691

(Notes on segment information, etc.)

Segment Information

1. Overview of Reporting Segments

The Company's reporting segments are those of the Company's constituent units for which segregated financial information is available and is subject to periodic review by the Board of Directors in order to determine the allocation of management resources and evaluate performance.

The Company has three reporting segments: BtoB Business, BtoC Business, and Biomedical Business. The main contents of each segment are as follows.

Reportable segments	Description of Business
BtoB	We sell functional ingredients, health foods, and pharmaceuticals to food and pharmaceutical manufacturers, wholesalers (including cross-border e-commerce agents), and other businesses.
BtoC	We sell health foods, pharmaceuticals, quasi-drugs, and cosmetics directly to general consumers through our own advertising activities.
Bio Medical	We are engaged in research and development of antibody drugs using our proprietary chicken-derived antibody production technology "ALAgene technology" and research support business that undertakes proteome analysis.

2. Method of calculating the amount of sales, profits, losses and other items for each reporting segment

The method of accounting for the reported business segments is substantially identical to that described in the "Fundamental Material Matters for Consolidated Financial Statements" section. Profit in the reporting segment is a figure based on operating income.

3. Information on the amount of sales, profits, losses and other items for each reported segment

The previous fiscal year (August 1, 2024 to July 31, 2025)

(Millions of yen)

	Reportable segments				Other (Note) 1	sum	Adjustment amount (Note) 2	Amount recorded in the consolidated statements of income (Note)3
	BtoB	BtoC	Bio Medical	Total				
Sales								
Revenues from external customers	8,182	56,730	331	65,244	15	65,260	-	65,260
Transactions with other segments	-	-	-	-	-	-	-	-
Total	8,182	56,730	331	65,244	15	65,260	-	65,260
Segment profit (loss)	1,248	3,703	(378)	4,573	(10)	4,563	(2,195)	2,367
Other items								
Depreciation	346	23	92	463	-	463	269	732
Amount of amortization of goodwill	-	-	-	-	-	-	53	53

Note: 1. The "Other" category refers to business segments that are not included in the reporting segments and include the fund management business.

2. The adjustment amount is as follows:

(1) Adjustments for segment profit or loss (loss) of (2,195) million yen include (2,141) million yen in corporate expenses and amortization of goodwill of (53) million yen that have not been allocated to each reporting segment. Company-wide expenses include general and administrative expenses that are not attributable to the reporting segment.

(2) The adjustment amount of 269 million yen for depreciation and amortization for other items is depreciation and amortization related to company-wide expenses.

(3) The adjustment of 53 million yen for amortization of goodwill for other items is the amortization of goodwill that has not been allocated to each reporting segment.

3. Segment profit or loss (loss) is adjusted for operating income in the consolidated statements of income.

4. Segment assets and liabilities are not listed because they are not allocated to each segment for management decision-making.

The current fiscal year (August 1, 2025 to July 31, 2026)

(Millions of yen)

	Reportable segments				Other (Note) 1	sum	Adjustment amount (Note) 2	Amount recorded in the consolidated statements of income (Note)3
	BtoB	BtoC	Bio Medical	Total				
Sales								
Revenues from external customers	7,471	55,368	350	63,190	33	63,223	-	63,223
Transactions with other segments	-	-	-	-	-	-	-	-
Total	7,471	55,368	350	63,190	33	63,223	-	63,223
Segment profit (loss)	1,112	4,481	(838)	4,755	(13)	4,742	(2,109)	2,632
Other items								
Depreciation	368	28	70	467	-	467	234	702
Amount of amortization of goodwill	-	-	-	-	-	-	34	34

Note: 1. The "Other" category refers to business segments that are not included in the reporting segments and include the fund management business.

2. The adjustment amount is as follows:

(1) Adjustments for segment profit or loss (loss) of (2,109) million yen include (2,075) million yen in corporate expenses and amortization of goodwill of (34) million yen that have not been allocated to each reporting segment. Company-wide expenses include general and administrative expenses that are not attributable to the reporting segment.

(2) The adjustment amount of 234 million yen for depreciation and amortization for other items is depreciation and amortization related to company-wide expenses.

(3) The adjustment of 34 million yen for amortization of goodwill for other items is the amortization of goodwill that has not been allocated to each reporting segment.

3. Segment profit or loss (loss) is adjusted for operating income in the consolidated statements of income.

4. Segment assets and liabilities are not listed because they are not allocated to each segment for management decision-making.

Related Information

The previous fiscal year (August 1, 2024 to July 31, 2025)

1. Product and Service Information

Since the same information is disclosed in the segment information, it is omitted.

2. Regional Information

(1) Net sales

Since sales to external customers in Japan exceed 90% of sales in the consolidated statements of income, the description is omitted.

.

(2) Property, plant and equipment

Since there are no property, plant and equipment owned outside of Japan, the description is omitted.

The current fiscal year (August 1, 2025 to July 31, 2026)

1. Product and Service Information

Since the same information is disclosed in the segment information, it is omitted.

2. Regional Information

(1) Net sales

Since sales to external customers in Japan exceed 90% of sales in the consolidated statements of income, the description is omitted.
.

(2) Property, plant and equipment

Since there are no property, plant and equipment owned outside of Japan, the description is omitted.

Information on impairment losses on fixed assets by reporting segment

The previous fiscal year (August 1, 2024 to July 31, 2025)

Not applicable.

The current fiscal year (August 1, 2025 to July 31, 2026)

Not applicable.

Information on amortization and unamortized balances of goodwill by reporting segment

The previous fiscal year (August 1, 2024 to July 31, 2025)

(Millions of yen)

	Reportable segments				Adjustment amount (Note)	sum
	BtoB	BtoC	Bio Medical	Total		
Depreciation for the period	-	-	-	-	53	53
Balance at the end of the current fiscal year	-	-	-	-	71	71

Note: The amount of depreciation and amortization for the period and the adjustment amount of the balance at the end of the period are the amounts related to goodwill that have not been allocated to the reporting segments.

The current fiscal year (August 1, 2025 to July 31, 2026)

(Millions of yen)

	Reportable segments				Adjustment amount (Note)	sum
	BtoB	BtoC	Bio Medical	Total		
Depreciation for the period	-	-	-	-	34	34
Balance at the end of the current fiscal year	-	-	-	-	37	37

Note: The amount of depreciation and amortization for the period and the adjustment amount of the balance at the end of the period are the amounts related to goodwill that have not been allocated to the reporting segments.

Information on Negative Goodwill Accrual Gains by Reporting Segment

The previous fiscal year (August 1, 2024 to July 31, 2025)

Not applicable.

The current fiscal year (August 1, 2025 to July 31, 2026)

Not applicable.